Abstract
The design and development of new radiohalogenated tracers for in vivo measurement of brain receptor related processes is due, to its complexity, the work of pharmaceutical companies or large multidisciplinary research groups. For the development of radiopharmaceuticals generally a compound is chosen based on its known pharmacological properties and a strategy must be developed to introduce the radioisotope.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J. Mertens, and M. Gysemans, CuI+ assisted nucleophilic exchange radiohalogenation: application and mechanistic approach, in: New Trends in Radiopharmaceutical Synthesis, Quality Assurance, and regulatory Control, A.M. Emran, Plenum Press, New York and London (1991).
I. Nakatsuka, H. Saji, K. Shiba, H. Shimizu, M. Okuno, A. Yoshitake, and A. Yokoyama, In vitro evaluation of radioiodinated butyrophenones as radiotracer for dopamine receptor study, Life Sci, 41:1989–1997 (1987).
J.E. Leysen, W. Gommeren, J. Mertens, W.H.M.L. Luyten, P.J. Pauwels, M. Ewert, and P. Seeburg, Comparison of in vitro binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D2S and D2L receptors and for D2 receptors in rat striatal and mesolimbic tissues, using [125I]-2′-iodospiperone, Psychopharmac., 110:27–36 (1993).
J. Mertens, C. Piron, F. De Geeter, L. Christieans, R. Cantineau, M. Guillaume, and J. Leysen, Evaluation of pure 2′-125I-spiperone as a promising tracer for in vivo D2 receptor study with SPECT, J. NucL Med., 30:926 (1990).
J. Mertens, “Clustered lipophilic compensation” a new concept in the development of lipophilic radioiodinated and brominated receptor tracers, J. Lab. Comp. Ratiopharm., 30:363 (1991).
J.C. Baron, Y. Samson, D. Comar, C. Crouzel, P. Deniker, Y. Agid, Etude in vivo des récepteurs serotoninergiques centraux chez l’homme par tomographic à émission de positrons, Rev. Neurol., 141:537–545 (1985).
C. Lemaire, R. Cantineau, M. Guillaume, A. Plenevaux, L. Christiaens, Fluorine-18-Altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats, J. Nucl. Med., 32:2266–2272 (1991).
H. D’haenen, A. Bossuyt, J. Mertens, C. Bossuyt-Piron, M. Gysemans, and L. Kaufman, SPECT imaging of serotonin2 receptors in depression, Psychiat. Res: Neuroimaging., 45:227–237 (1992).
M.R. Kilbourn, and M.R. Zalutsky, Research and clinical potential of receptor based radiopharmaceuticals, J. NucL Med., 26:655–662 (1985).
J. Mertens, M. Gysemans, C. Piron, M. Thomas, High yield preparation of pure 2-radioiodo-ketanserin of high specific acitivity, a serotonin S2 receptor tracer for SPECT, J. Lab. Comp. Ratiopharm., 28:731–738 (1990).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Mertens, J., Moereels, H., Gysemans, M., Terriere, D., Thomas, M., Leysen, J. (1995). Design, Structure-Activity, Labelling and Purity in the Development of Receptor Interacting Radiohalogenated Tracers. In: Emran, A.M. (eds) Chemists’ Views of Imaging Centers. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9670-4_27
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9670-4_27
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9672-8
Online ISBN: 978-1-4757-9670-4
eBook Packages: Springer Book Archive